News Release: The Immune Response Corporation Announces Publication of Results from Thailand Clinical Trial
CARLSBAD, Calif., Aug. 25 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR - news) announced today the publication of results from an open-label clinical trial being conducted in Thailand using REMUNE(TM). The data was published in the journal AIDS (Volume
12, Number 12 1998). The company believes this paper, entitled ''Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand,'' may supportprevious findings regarding the activity of REMUNE. This trial involved the follow-up on 30 Thai individuals infected predominantly with the subtype E strain of HIV-1 who were not taking antiviral drug therapy. At 60 weeks of follow-up after treatment with REMUNE, subjects had a significant
increase in CD4 cell count (p<0.0001), CD4 cell percentage (p<0.0001), CD8 percentage (p<0.0001) and body weight (p<0.0001) compared to pretreatment levels. A decrease in viral loadwas observed in 14 individuals with detectable viral load at baseline (p=0.04). Furthermore, 23 of 30 (77%) subjects developed HIV-specific immune responses. An ongoing placebo-controlled clinical trial is being conducted in Thailand in up to 300 HIV-infected individuals. These clinical trials are being conducted by investigators from Mahidol University in Bangkok, Thailand.
Dr. Vina Churdboonchart, Principal Investigator, noted ''These results are encouraging and we are hoping to replicate these findings in ongoing placebo-controlled trials of REMUNE in Thailand where access to antiviral drugs is limited and new effective therapies for HIV-1 infection are urgently needed.''
In clinical trials conducted to date with REMUNE, with or without antiviral drug therapy, the most frequently reported side effects include local transient pain, soreness and redness at the site of
injection, muscle aches, fatigue and headache.
REMUNE is an immune-based therapy currently in development by The Immune Response Corporation and Agouron Pharmaceuticals, Inc. for the treatment of HIV infection. |
